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March 23, 2010:1278–82PAUG) accounts for the majority of the variance in central pulse
ressure (cPP) and is unrelated to pulse wave velocity (PWV). In
ine with most authorities (including those providing the editorial
ccompanying our paper), we attributed PAUG to wave reflection
2–4). Drs. Cameron and Dart’s “alternate” explanation of our data
s based on the assumption that the ratio of femoral artery to
bdominal aortic diameter (DFA) is a measure of wave reflection.
iven that wave reflection depends on discontinuities in imped-
nce along the arterial tree, DFA could at best be a surrogate
easure of increased impedance due to diameter decrease. How-
ver, DFA cannot be regarded as a measure of wave reflection. Of
ll arterial dimensions measured in our study, PAUG was most
losely related to DFA, and we made the point that this was
onsistent with reflection (as measured by PAUG) being influ-
nced by serial change in diameter.
We acknowledge that PAUG may not be the “best” measure of
ave reflection and the limitations of the transfer function, which
e stressed in our paper. However, we would also point out that
he separation of pressure waves into forward and backward waves
s not without its problems and relies on several assumptions.
ecause PAUG is a major component of cPP, it will be important
o identify the exact determinants of PAUG. Any theoretical
nalysis needs to be confirmed by careful measurement of proper-
ies along the arterial tree during interventions that selectively
odulate potential determinants of PAUG.
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lternative Interpretation
f Mitochondrial Metabolic
hanges in Atrial Tissue of
ype II Diabetic Human Heart
nderson et al. (1) presented an elegant study in which they assessed
he rates of substrate oxidation and reactive oxygen species productionf atrial tissue from diabetic patients with normal ejection fraction
ndergoing coronary artery bypass graft. The authors observed re-
uced mitochondrial respiratory capacity with palmitoyl-L-carnitine
nd glutamate as substrate, but not with pyruvate and succinate, as
ell as augmented reactive oxygen species production in the diabetic
roup when compared with nondiabetic patients. They then sug-
ested that the existence of myocardial insulin resistance may explain
he observed defects in oxidative capacity. However, 3 major concerns
ave not been addressed in the manuscript, which render the
onclusions questionable.
First, the authors refer to the decreased respiratory capacity with
almitoyl-L-carnitine as a defect in fatty acid oxidation, not
onsidering the following interpretation. The authors used gluta-
ate, a complex I substrate, and succinate, a complex II substrate.
ecause glutamate respiration was reduced and succinate was
ormal, a defect may be located at the level of complex I. This
onclusion would be supported by the finding of decreased
espiratory rates of palmitoyl-L-carnitine, but not by normal
yruvate respiration, which also should be reduced in this case. In
nalogy to this reasoning, the conclusion of decreased fatty acid
xidation based on the reduced palmitoyl-L-carnitine–supported
espiration can be challenged by their reduced glutamate respira-
ory measurements, because levels of glutamate and pyruvate
hould be normal. Thus, the conclusion that fatty acid oxidation is
educed, based only in respiratory measurements, is questionable.
Second, the authors suggest that cardiac insulin resistance may
e the cause for the observed alterations and refer to the results
rom Boudina et al. (2) obtained in a cardio-specific insulin
eceptor knockout mouse. To date, there is no consensus regarding
hether cardiac insulin resistance is present in both type I and type
I diabetes, and the authors did not assess the activity of insulin
ignaling cascade in their study. In contrast, ischemic heart disease
as been shown to be accompanied by cardiac insulin resistance
3,4). Considering that all patients including the control group had
oronary artery disease, it is most likely that if cardiac insulin
esistance was present in the diabetic patients, it could be present
n the control group as well and therefore would not explain the
etabolic changes observed.
Third, there were no data regarding the number of compro-
ised vessels in each group. Since type II diabetes is associated
ith increased risk of coronary heart disease (5), it is unclear
hether the differences among groups are related to the extension
f vessel disease.
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eply
he letter from Drs. Amorim and Doenst regarding an interpre-
ation of the data presented in our recent study (1) underscores the
mmense complexity of discerning the interplay between the
etabolic syndrome, coronary artery disease (CAD), diabetes, and
eart failure.
Drs. Amorim and Doenst rightly point out that the existence of
ardiac insulin resistance (cIR) in diabetes is still a matter of debate
nd that attributing the alterations in mitochondrial metabolism of
almitoyl-L-carnitine and glutamate that we observed in the
iabetic human hearts to cIR is questionable. We agree with this
tatement and wish to emphasize that this interpretation of the
ata was one of several put forth, along with the possibility that
iabetic hearts may not be responding appropriately to nutritional
tatus and substrate availability, that key mitochondrial enzymes in
he metabolic pathway for these substrates may be defective, or
oth. It also should be pointed out that in those studies that have
eported cIR, the question of when cIR develops during the course
f metabolic syndrome or diabetes also seems to be unresolved.
lthough many studies suggest that cIR is a strong predictor of the
evelopment of heart failure (2,3), other studies have shown that
eart failure can cause insulin resistance (4,5), thereby clouding the
ause-and-effect relationship between the two. With respect to our
tudy, we believe that although it is possible the nondiabetic
atients have cIR, the additional stress of overt diabetes has pushed
he diabetic hearts closer to a phenotype resembling that of heart
ailure (i.e., reduced fatty acid oxidative capacity and oxidative
tress). In any case, because these samples were obtained from
atients in a fasted state, measurement of insulin signaling proteins
n the heart samples would be of indeterminate value.
We also concur that the altered respiratory capacity seen in the
iabetic human heart tissue is not the result of a defect of
itochondrial complex I, but instead believe it to be the result of
pecific defects in the mitochondrial enzymes responsible for the
xidation of these substrates. Recent studies in animal models of
eart failure have shown defects that are strikingly similar (6,7),
ending further support to the proposition that the hearts of the
iabetic patients with CAD have a metabolic phenotype that is
loser to heart failure than nondiabetic, age-matched individuals
ith CAD alone.
Finally, because these data were generated in mitochondrial
reparations from atrial tissue and not ventricular tissue, it is
oubtful that ischemia concomitant to CAD is playing a role,
lthough it cannot be completely ruled out.
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tatins in Acute Coronary
yndromes and Genetic Insight
he report of Gibson et al. (1) addresses the issue of whether
ntensive statin therapy (atorvastatin 80 mg/day) leads to a greater
eduction in major adverse cardiac events (MACE) among patients
ndergoing percutaneous coronary intervention (PCI) for acute
oronary syndrome, compared with patients randomized to mod-
rate statin therapy (pravastatin 40 mg/day). Intensive statin
herapy reduced MACE and target vessel revascularization signif-
cantly more than standard statin therapy, and the authors noted
hat the effect was independent of low-density lipoprotein choles-
erol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP)
evels and might be related to pleiotropic effects of statins. This
eport is similar to the original PROVE IT–TIMI 22 (Pravastatin
r Atorvastatin Evaluation and Infection Therapy–Thrombolysis
n Myocardial Infarction 22) results and raises 3 additional
uestions of clinical importance. First, was the MACE benefit
rimarily in favor of carriers of the KIF6 polymorphism? Second,
as the time to benefit shorter in carriers of the KIF6 polymor-
hism? And third, why were differences in LDL-C and hs-CRP
evels not associated with clinical outcome?
The event rate for the primary composite end point in the
ibson analysis was 21.5% in the atorvastatin 80-mg/day group,
ompared with 26.5% in the pravastatin 40-mg/day group for a
